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reimbursable drugs, has abolished the requirement, highlighting the potential prac-
tical difficulties in obtaining such prices. One country (Switzerland) has recently 
proposed amendments to its IRP methodology to focus on discounted rather than 
listed prices. ConClusions: IRP is increasing as a core market access risk globally, 
with the knock-on implications of low prices or price cuts in one country into other 
countries becoming a more tangible and complex threat. IRP is increasing both 
in terms of geographic scope and also in terms of the precise method of use. The 
shift from using manufacturing prices towards discounted prices, and the increas-
ing transparency over net prices, represent a significant ongoing threat, and the 
practical implications are wide-ranging. It has the counter-productive effective of 
rendering pharmaceutical companies less willing and likely to engage in discounts.
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Faster Drug Market access In Italy: Is class c-nn tHe answer?
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objeCtives: Implemented by the Italian Medicines Agency (AIFA) in 2013, Class 
C-nn (C – non negotiated) was created to make all drugs approved by the European 
Medicines Agency (EMA) available to patients at prices set by manufacturer before 
AIFA’s pricing & reimbursement (P&R) decision. The study’s objective is to challenge 
the intended purpose of Class C-nn and its impact on the time to market. Methods: 
Drugs assigned to Class C-nn between January 2013 and April 2015 were consid-
ered for the analysis. Nine official dates, representing key milestones in the national 
market access process, from EMA approval to the P&R decision were identified; the 
period from AIFA’s Technical-Scientific Committee’s (CTS) opinion to the P&R deci-
sion was the main focus. The negotiation lengths were compared to those prior to 
the introduction of Class C-nn. Moreover, the relationship between drug-specific vari-
ables (e.g., therapeutic area, presence of registry, orphan/innovative status) and the 
negotiation length was analyzed. Results: Out of 137 products assigned to Class 
C-nn, 43 completed the P&R process. The average time from EMA approval and CTS’s 
opinion to the P&R decision totaled 393 days (95% CI 353-432) and 159 days (95% 
CI 137-181) respectively. The analysis revealed longer negotiations for oncology and 
diabetes drugs versus drugs targeting other therapeutic areas. Negotiations for drugs 
included in the AIFA monitoring system were almost twice as long as products not 
monitored. It is worth noting that orphan drugs as well as drugs with an innovative 
status did not result in shorter negotiation processes. Furthermore, a negligible num-
ber of drugs accessed the market with C-nn status at freely set prices. ConClusions: 
Implementing Class C-nn has not significantly impacted the time to reimbursement 
in Italy. Most companies prefer to not submit freely set prices prior to the P&R deci-
sion, thus neglecting the possibility of early market access.
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tHe enD oF tHe excePtIonal FInancIng oF erytHroPoIesIs-
stIMulatIng agents In FrencH HosPItals: wHat are tHe IMPacts For 
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objeCtives: Erythropoiesis-stimulating agents (ESAs) are not anymore part of 
listed drugs exceptionally financed in addition to DRGs tariffs, which use and 
expenditures are monitored by the authorities. The amount of ESAs has been 
included in French DRGs tariffs since March 2014. The objective is to assess 
the impact on both the activity and the budget of Public Hospitals of Paris (AP-
HP). Methods: A before-after study (March-September in 2013 versus in 2014) 
was conducted in acute care hospitals of AP-HP. Data from PMSI hospital database 
(French medical information system program) and finance and logistics software 
(SAP), were used to estimate the number and costs of DRGs with ESAs use in 2014, 
from 2013 data. Two hypotheses were performed: A) the activity was constant, 
B) it depended on ESAs volumes delivered by hospital pharmacies to care units 
(Wilcoxon test). Then a budget impact (BI) analysis was conducted, considering: i) 
costs of dialysis and extra dialysis DRGs with ESAs use in 2013 versus in 2014, ii) 
the loss of money earned in 2013 by negotiating ESAs prices below the reimbursed 
tariffs, iii) costs of ESAs included in the DRGs tariffs in 2014. Results: 20 hospitals 
were included. The number of DRGs with ESAs increased of 264 (+5%) dialysis DRGs 
and 80 (+2%) other DRGs under hypothesis A whereas it decreased of 449 (-9%) 
dialysis DRGs and it increased of 346 (+9%) other DRGs under hypothesis B, but this 
differences are not significant. Nevertheless, the global BI is between -€ 1,018,476 
(hypothesis A) and -€ 695,693 (hypothesis B) in 7 months. ConClusions: This 
study shows no significant impact on the hospital activity but a negative BI for 
AP-HP. This infers that the DRG-based payment may be not appropriate to the 
chronic renal failure. Besides, the French Health Ministry is working on a patient 
pathway-based payment.
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objeCtives: Aim: To investigate compliance with the recently introduced (November 
2013) system of active substance-based generic substitution and reference pricing (GS/
RP) in Ireland. Under GS/RP, a fixed drug price is paid by the Health Service Executive 
(HSE). Where a patient requests a premium-priced product, the patient must pay the 
difference. A prescriber may alternatively request ‘Do not substitute’(DNS), in which 
case the HSE pays the difference, similar to the Danish model where the prescriber 
may apply for reimbursement on behalf of patients. This study characterised Irish 
DNS trends and costs following GS/RP introduction. Methods: Pharmacy claims 
data from the ‘General Medical Services’ scheme, January 2013-October 2014 inclu-
sive, were analysed using SAS®v9.3. Drugs for which premium-priced products were 
available were studied where 6 months of follow-up data existed post policy introduc-
was approved in February 2015 but has not been assessed yet. Of note, MA for MACI® 
and Provenge®were suspended for commercial reasons. ConClusions: Market 
access of ATMPs is challenging as the evidence available at market launch might 
not be sufficient to address the HTA agencies’ expectations. Adaptive pathways for 
licencing and coverage of drugs might be a relevant approach for these medicines 
to reduce uncertainty through real-world data collection post-launch.
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objeCtives: In recent years pharmaceutical market in Poland was impacted by 
the new Reimbursement Act that came into the force on 1st January 2012. After 
a long period of stagnancy in pricing & reimbursement policy the new Act intro-
duced substantial changes. It was strongly awaited by all stakeholders. The aim of 
this study was to investigate the impact of the new Reimbursement Act on phar-
maceutical industry and market access. Methods: Medline, grey literature and 
other internet resources (health authorities’ websites, pharmaceutical blogs and 
discussion forums) search focused on implications of the new drug regulation in 
Poland. Results: The main objectives of the Reimbursement Act included improve-
ment of pricing and reimbursement process transparency, increase in overall access 
to medicines and to innovative drugs in particular, lowering patients’ co-payment 
and reduction of National Health Fund (NFZ) spending on reimbursable drugs. 
However, in pharmaceutical industry opinion the reform did not increase trans-
parency of reimbursement decision-making in Poland. While NFZ is considered to 
be the main beneficiary, industry revenue decreased. The new Act forced substantial 
adjustments in business models and incurred additional costs resulting from the 
need for intense monitoring of dynamically changing market situation. Access to 
innovative therapies is gradually improving with 29 innovative molecules intro-
duced to reimbursement lists between January 2012 and June 2014. NFZ expenditure 
on innovative drugs increased from 0,2% to 3% of total drug expenditure between 
2012 and 2014. In spite of some improvements, access to innovative therapies 
in Poland remains lower than in developed EU countries. ConClusions: New 
law influenced drug market substantially. It evoked many controversies and 
discussions. Overall, introduced changes are perceived as unfavorable by pharma-
ceutical industry. However, savings have been reallocated to fund new innovative 
therapies. Access to such therapies is slowly improving, but is still limited as com-
pared to Western EU countries.
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objeCtives: This study intends to provide an overview of regulatory updates on 
Early Access Programmes (EAPs) in 21 countries and score the drivers of successful 
implementation by examining the national regulatory framework, process, require-
ments, and revenue opportunity. Methods: A literature review was conducted 
from government and health authority websites, Pubmed, and grey literature to 
identify EAP regulation, practice, and updates. We inputted information in an Excel 
template and aggregated it with 3 indicators (clarity of the process, ease of imple-
mentation, and revenue possibility). The 3 indicators were ranked from 1 (least feasi-
ble, multiple barriers) to 4 (most feasible, least barriers). Geographical scope covered: 
France, Germany, Italy, Spain, UK, Austria, Belgium, Denmark, Norway, Poland, 
Portugal, Sweden, Switzerland, Australia, Brazil, Canada, Israel, New Zealand, South 
Africa, South Korea, and Turkey. Results: Regulatory updates were found in the 
countries with variable magnitude. Scores as follows: ++++: France; +++: Spain, 
Italy, Austria, Denmark, Norway, Canada, Israel, Australia, and New Zealand; ++: 
Germany, Portugal, Sweden-CUP, Switzerland, Brazil, South Africa, South Korea, 
Turkey; and +: UK, Belgium, and Poland. France, a pioneer in EAPs, scored highest. 
+++ countries have clear processes, free pricing, and possible reimbursement. In ++ 
countries, EAP sales are not possible. For UK and Belgium, processes are relatively 
new (2014) with steep fees, and are yet to be validated. Sales are not possible in 
the UK and details for Belgium are still unavailable. ConClusions: EAP policies 
are evolving fast, signaling high interest, and will likely be increasingly important. 
Regulatory changes tend to ease and expedite the EAP process but fees are being 
imposed and sales limited in newer regulations. It is yet to be seen how updates will 
affect the market access condition of products undergoing EAP. Companies must be 
abreast with changes to capitalise on early access opportunities and mitigate risks.
PHP29
tHe exPansIon oF use oF DIscounteD PrIces For InternatIonal 
reFerence PrIcIng PurPoses
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objeCtives: The goal of this research is to understand the extent to which payers 
around the world are using discounted or net prices for international reference 
pricing (IRP) purposes as an alternative to list, manufacturing or wholesale prices. 
The research also examines what sources are being used to obtain these discounted 
prices. Methods: Primary research was conducted with payers in 45 countries to 
establish the methodology of IRP in those countries. Specific questions were asked 
around both the current and potential future use of different types of prices for IRP. 
This was supplemented with secondary search and literature reviews of legislation 
and healthcare sources related to IRP to understand mechanisms of IRP. Results: 
Overall, it was shown that 8 countries used some form of discounted prices for IRP 
purposes, and that the number of countries is increasing. In addition, one country 
(Bulgaria), which previously had a requirement to reference discounted prices for 
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of novel drugs to patients and fosters divergence in reimbursement status. The 
objectives were to identify differences in REA by EU-HTA agencies, discuss the 
impact of this variation on time to patient access and assess the potential benefits 
of a centralized REA. Methods: Differences in clinical assessment across EU-HTA 
bodies were analysed for selected EMA approved Novartis drugs (internal data and 
structured telephonic interviews with Novartis Country Pharma Organisations 
(CPOs) and drugs marketed by other companies (literature review). Results: 
Differences in acceptance of comparators, subgroups and end-points were seen 
in REA across countries. Although fingolimod, secured wide reimbursement in EU 
for Relapsing-Remitting Multiple Sclerosis (RRMS), HTA bodies differed in their 
end-points’ acceptance. Example, UK accepted annual relapse rate, disability pro-
gression and MRI-lesions, while Germany didn’t accept the latter as end-point. 
Variations were seen in countries’ requirements for additional analysis to support 
REA. Example, Germany granted a ‘small additional benefit’ rating for Rapidly 
Evolving Severe RRMS subgroup based on indirect comparison, while, even an 
additional mixed treatment comparison couldn’t support REA for this subgroup in 
UK. Amongst non-Novartis drugs; pertuzumab review by IQWIG and GBA resulted 
in different end-point acceptance, with negative and restricted access recom-
mendation, respectively. For sofosbuvir, HTA bodies differed from EMA label and 
saw clinical value only in some patient subgroups. Example, IQWIG recommended 
the drug for only HCV genotype-2 whereas ZIN (Netherlands) recommended it for 
genotype-1 and 4. CPOs’ survey indicated that centralized EU-REA could reduce 
time to patient access (by ~3-4 months), through avoiding repetitive clinical 
evaluation and saving time on pricing/reimbursement pathway. ConClusions: 
Harmonized REA has the potential to reduce delay in patient access, strengthen 
the equity of care and increase predictability of expectations from pharmaceutical 
companies’ research programs.
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objeCtives: We aimed to present the characteristics and challenges of the external 
reference pricing (ERP) from the perspective of Slovenia. Methods: The literature 
search was made for the information on ERP in countries included in the Slovenian 
country basket and countries that refer Slovenia. The data on characteristics of the 
ERP such as country basket composition, calculation of the reference price, scope 
of medicines, type of comparable price and use of the ERP as main or supportive 
criterion were taken into account. Results: Slovenia defines medicine prices based 
on the prices in Austria, Germany and France, while 17 countries refer Slovenia. 
Slovenia’s greatest potential impact concerns the medicine prices in Croatia, Bosnia, 
Serbia and Portugal that refer only three countries. Their calculation method is an 
average price of reference countries, indicating that the role of Slovenia is not as 
large as it could be if the calculation method was the lowest price or the average of 
lowest three prices in reference countries. However, Slovenia does not have a greater 
role in countries calculating reference price as the lowest price or the average of 
the three lowest prices, while most of those countries refer 20 or more countries 
and Slovenia is not necessary the country with the lowest medicine price. The 
ERP represents a special challenge for countries as Slovenia that do not represent 
a large medicines market and try to reduce medicine costs to a greater extent 
than others with potential risk of medicines withdrawal. Slovenia does not have 
a direct impact on medicine prices in countries using ERP as supportive criterion. 
Further, Slovenia and Austria refer each other, representing an overlapping connec-
tion. ConClusions: The small pharmaceutical market and potentially large impact 
on the prices of medicines in other countries places Slovenia in a special position.
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objeCtives: This study appraised the health professionals and managers’ value 
judgments in Brazilian HTA process, through a new method of research that 
addresses clinical scenarios to simulate real world dilemmas and support budget 
allocation. The decisions should be made under clinical and epidemiological aspects, 
and, also, economic, social, ethical and cultural factors. The main objective was to 
evaluate how these factors have influenced the decision makers in HTA resources 
allocation. We agreed to call this model by Decision Making Clinical Scenarios 
(DMCS). Methods: This study was conducted through a decision making ques-
tionnaire with four clinical scenarios involving HTA. These scenarios introduced 
issues involving value judgments, preferences and structuring choices, considering 
a severe budget restraint. The presented trade-offs were related to health policies, 
such as budget impact, sources of funding, eligible patients, technology charac-
teristics and disease epidemiology. Results: The results showed a conservative 
trend. In all three scenarios involving some form of technological incorporation, the 
most chosen option was to avoid incorporation. Alternatives of funding, as reduc-
tion/extinction of current healthcare programs and creation of a new tax, were not 
accepted as solutions. In budget allocation between prevention and treatment pro-
grams, respondents were suited to a preventive long-term strategy. ConClusions: 
The scenarios have been shown understandable. The absolute scarcity of resources 
clearly influenced the results. In search of a paradigm for decision making, most of 
respondents prioritized to save resources, instead of incorporating the technologies. 
We concluded that managers are not guided only by clinical benefit of a decision. 
They valorized the importance of funding mechanisms and budget control that 
enable incorporation, considering economic, social, ethical, and structural aspects. 
This study model seems to be useful to evaluate the trends of conduct of decision 
makers. This model can be used in further researches, bringing different factors and 
criteria into discussion, through clinical real world situations.
tion (n= 7 drugs). For each claim the source of payment and price difference, where 
applicable, were deduced from the recorded expenditure. Trends, including costs to 
the HSE, were monitored over time. The impact of time since policy introduction and 
price difference magnitude on DNS likelihood (HSE payment) were explored using 
logistic regression. Results: Overall, generic drug dispensing rose from 79% to 92% at 
six months following policy introduction. However, within premium-priced products 
dispensed (8% overall), the proportion of DNS increased from 15% to 39%. Time since 
policy introduction and magnitude of price difference were both positive predic-
tors of DNS (versus patient payment) (p< 0.001). ConClusions: GS/RP successfully 
increased generic dispensing. However, estimated DNS rates increased significantly in 
the first 6 months, incurring additional costs to the HSE, and were predicted by higher 
potential costs to the patient. These trends suggest that the burden of co-payment 
within GS/RP is increasingly being passed to the health service. With continual roll-
out of GS/RP, interventions may be required to ensure DNS occurrences appropriately 
reflect medical need.
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objeCtives: The appropriate use of drugs including antibiotics is crucial towards 
achieving better quality of life. The aim of this study was to assess the prescrib-
ing practices and antibiotic use patterns in the Accident and Emergency (A&E) 
Department of the Bahawal Victoria Hospital (BVH), Bahawalpur, Pakistan. Methods: 
A descriptive, non-experimental, retrospective and cross sectional study design was 
employed. A sample of 4,320 prescriptions (systematic random sampling) was drawn 
out of the total prescriptions written during January to December 2014. The standard 
World Health Organization/International Network for Rational Use of Drugs (WHO/
INRUD) prescribing indicators were used to enumerate prescribing practices of the 
physicians. Published ideal standards for each of the indicators were used to identify 
the irrational drug use. An additional indicator (the percentage share of each anti-
biotic) was also determined. Results: The average number of drugs per encounter 
was 2.3 (SD = 1.3) (optimal value = 1.6–1.8), the drugs prescribed by generic name 
were 83.1% (optimal value = 100%), the encounters with an antibiotic and injec-
tion prescribed were 52.4% (optimal value = 20.0–26.8%) and 98.0% (optimal value 
= 13.4–24.1%) respectively and the drugs prescribed from Essential Drugs List were 
81.5% (optimal value = 100%). Out of 52.4% (n = 2,262) prescriptions with antibiotics 
prescribed, 77.7% (n = 1758) had one antibiotic, 22.1% (n = 499) included two antibi-
otics, and only 0.2% (n = 5) had three antibiotics. Cephalosporins (81.5%), were the 
most commonly prescribed class of antibiotics followed by penicillins (6.4%) and 
fluoroquinolones (6.2%). Among the individual antibiotics, Ceftriaxone contributed 
the highest percentage share of 71.8% followed by cefotaxime (5.6%) and metronida-
zole (4.7%). The most frequently prescribed antibiotic combination was ciprofloxacin 
with metronidazole (52.1%). ConClusions: The irrational prescribing practices were 
common. Continuous education and training of the physicians is required to ensure 
rational prescribing of antibiotics and injections.
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objeCtives: The UK operates free pricing of new chemical entities (NCEs). The 
2014 PPRS was a radical departure from its predecessors, focussing on industry’s 
obligation to repay the Department of Health (DH) for growth in the NHS drug 
expenditure beyond certain limits. These repayments look set to exceed original 
estimates, reducing certainty for members of the voluntary scheme. The statutory 
regulations impose higher price cuts at the outset, ensuring those not in the PPRS 
do not have an advantage. As NHS sales from new NCEs launched after Jan 1st 2014 
are exempt from PPRS payment calculations, we show that the scheme favours 
those with products early in their life span. Methods: 15 case studies of small 
(n= 5), medium (n= 6) and large companies (n= 4) were reviewed to identify the 
implications for manufacturers with established portfolios compared to those with 
new launches after January 2014 under the PPRS and statutory scheme. We review 
legal options for companies who consider themselves unfairly treated. Results: 
Evidence exists of an imbalance in the PPRS impact, thus negatively affecting the 
UK as an early launch market. Companies have successfully challenged the appli-
cation of the statutory scheme price reductions to products already covered by a 
tender and the impact on international reference pricing. The scheme potentially 
amounts to an unlimited payment to the DH and worryingly payments are allo-
cated to an undefined pot rather than to the original budget holder. Price rises are 
possible, subject to justification on the basis of eight main factors. ConClusions: 
Companies supplying mainly mature products that offer the NHS good value for 
money are disproportionately affected compared with larger companies with a 
broader international portfolio, leading to an increase in price rise applications. 
Companies with a pipeline of NCEs, which are commonly more expensive, are the 
winners despite driving greater NHS expenditure.
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objeCtives: Heterogeneity in interpreting same clinical data of EMA approved 
medicines by HTA agencies of EU member states potentially delays accessibility 
